Apollomics Inc.
No enriched coverage for $APLM in the last 7 days.
No SEC Form 4 filings for $APLM in the last 30 days.
Biotech stocks rose on multiple catalysts. CareDx (CDNA) jumped 35.6% after Medicare finalized an LCD covering its transplant molecular testing, effective Aug. 30, 2026. AtaiBeckley (ATAI) gained 33.4% on an Eli Lilly (LLY) acquisition deal up to $3.8B. Abbott (ABT) rose 10.7% after Q2 results and raised FY26 adjusted EPS outlook to $5.45-$5.60.
Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on oncology therapies, with a market capitalization of US$32.9 million. The company faces significant risks including negative shareholder equity, substantial share dilution, and volatile share price, but has seen some narrowing of net losses and revenue growth in recent earnings reports. Apollomics continues clinical development of vebreltinib and uproleselan, with recent updates on trial results, funding, and board changes.
Recent APLM coverage spans financial news and market movers.
Compliance restoration reduces delisting risk, which can re-rate the equity and improve liquidity/financing optionality.
Near-term upside bias from de-risking Nasdaq compliance risk; follow-through depends on upcoming clinical milestones.
The recent bearish sentiment (-62.7%) and financial challenges suggest increased risk for short-term traders, but potential for long-term value exists if clinical trials succeed.
The settlement of litigation is a positive development, reducing legal risks and potentially stabilizing the company's outlook.
The settlement of litigation reduces legal and financial uncertainties for Apollomics, potentially stabilizing its stock performance in the near term.
alphai scores every news story that mentions APLM with an AI model for sentiment and relevance, and aggregates insider trades from Apollomics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech stocks rose on multiple catalysts. CareDx (CDNA) jumped 35.6% after Medicare finalized an LCD covering its transplant molecular testing, effective Aug. 30, 2026. AtaiBeckley (ATAI) gained 33.4% on an Eli Lilly (LLY) acquisition deal up to $3.8B. Abbott (ABT) rose 10.7% after Q2 results and raised FY26 adjusted EPS outlook to $5.45-$5.60.
7 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readApollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on oncology therapies, with a market capitalization of US$32.9 million. The company faces significant risks including negative shareholder equity, substantial share dilution, and volatile share price, but has seen some narrowing of net losses and revenue growth in recent earnings reports. Apollomics continues clinical development of vebreltinib and uproleselan, with recent updates on trial results, funding, and board changes.
4 min readFOSTER CITY, Calif., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( "Apollomics" or the "Company" ) ( NASDAQ:APLM ) announced today entering into a settlement agreement ( the "Settlement Agreement" or the "Agreement" ) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group ...
2 min readFOSTER CITY, Calif., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( "Apollomics" or the "Company" ) ( Nasdaq: APLM ) announced today entering into a settlement agreement ( the "Settlement Agreement" or the "Agreement" ) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group ...
2 min readFOSTER CITY, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( Nasdaq: APLM ) ( "Apollomics" or the "Company" ) , a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ( "Board" ) ...
2 min readFOSTER CITY, Calif., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( NASDAQ:APLM ) ( "Apollomics" or the "Company" ) , a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ( "Board" ) ...
2 min readShares of Lucas GC Limited ( NASDAQ:LGCL ) rose sharply in pre-market trading after announcing 1H 2025 financial results. Lucas GC posted H1 EPS of $1.47 on sales of $54.008 million. Lucas GC shares jumped 36.2% to $3.73 in the pre-market trading session.
3 min readNasdaq Hearing Cancellation and Continued Listing Nasdaq Hearing Cancellation and Continued Listing ...
2 min readFOSTER CITY, Calif., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Apollomics Inc. ( NASDAQ:APLM ) ( "Apollomics" or the "Company" ) , today announced the following company operational update.
2 min read
